Risk factors for development or deterioration of Graves' ophthalmopathy
about
Orbital radiotherapy for adult thyroid eye diseaseThe evaluation and treatment of graves ophthalmopathyCurrent concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.Structural-Functional Features of the Thyrotropin Receptor: A Class A G-Protein-Coupled Receptor at WorkHypoxia increases adipogenesis and affects adipocytokine production in orbital fibroblasts-a possible explanation of the link between smoking and Graves' ophthalmopathy.Failure of radioactive iodine in the treatment of hyperthyroidism.The evolving role of selenium in the treatment of graves' disease and ophthalmopathy.Graves' ophthalmopathy: a review of immunogenetics.Incidence and clinical presentation of moderate to severe graves' orbitopathy in a Danish population before and after iodine fortification of salt.An overview of thyroid eye diseaseGenetic associations of FCRL3 polymorphisms with the susceptibility of Graves ophthalmopathy in a Chinese population.Cigarette Smoke Extract-Induced Oxidative Stress and Fibrosis-Related Genes Expression in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.Predictive Factors of Development of Graves' Ophthalmopathy for Patients with Juvenile Graves' Disease.Thyroid associated orbitopathy: Understanding pathophysiology.Comparison of Early Total Thyroidectomy with Antithyroid Treatment in Patients with Moderate-Severe Graves' Orbitopathy: A Randomized Prospective TrialNovel insights on thyroid-stimulating hormone receptor signal transduction.Is Recombinant Human TSH a Trigger for Graves' Orbitopathy?Genotype and phenotype predictors of relapse of graves' disease after antithyroid drug withdrawalTime course of Graves' orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer.Prevalence of Graves' ophthalmopathy in patients with Graves' disease presenting to a referral centre in north India.Thyroid physiology and autoimmunity in pregnancy and after delivery.Treatment options for Graves' orbitopathy.Medical management of thyroid eye disease.Extrathyroidal manifestations of Graves' disease: a 2014 update.The Aryl Hydrocarbon Receptor and Its Ligands Inhibit Myofibroblast Formation and Activation: Implications for Thyroid Eye Disease.Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.Socioeconomic Disparities in the Presentation and Treatment of Graves' Disease and Thyroid Eye Disease.Thyroid eye disease: a review.Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management.Novel single-nucleotide polymorphisms in the calsequestrin-1 gene are associated with Graves' ophthalmopathy and Hashimoto's thyroiditis.Update in oculoplastic imaging.PPARg2 Ala¹² variant protects against Graves' orbitopathy and modulates the course of the disease.Thyroid peroxidase antibody positivity and triiodothyronine levels are associated with pediatric Graves' ophthalmopathy.RNA-Sequencing Gene Expression Profiling of Orbital Adipose-Derived Stem Cell Population Implicate HOX Genes and WNT Signaling Dysregulation in the Pathogenesis of Thyroid-Associated Orbitopathy.Raising awareness of Graves' orbitopathy with early warning cards.PTX3: A Potential Biomarker in Thyroid Associated Ophthalmopathy.Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy.
P2860
Q24201984-8BCE34D6-2F05-4118-90B1-703A460C0DBBQ26862144-50D2031D-EAD6-48FF-877F-6C101042A2A9Q27691806-3BF4181D-237D-4EF7-86E6-A1E5BD2B107FQ30401802-34529568-6DCE-4074-82AB-BB54223E7F79Q33794950-08911B69-EA31-4EE7-8544-43B889AC01D0Q35088255-8E59568D-A941-4370-8DA3-EEA6D717DA39Q35725329-8ED641BB-8F4B-43C3-ACF6-9058CB83D96CQ35731002-E6EACFC9-02E4-457C-AEE5-3DAE9BEB8ADFQ36069781-1CE8A615-A33D-4437-8253-490974CA253BQ36305798-0FF7379B-330E-40E2-9575-F8E0BFE1CFEBQ36318253-DE586A16-6F24-436A-B542-1EB40950726EQ37010019-01637852-4DE4-4753-BB94-EE7729263733Q37054144-784DB311-E57B-4472-9155-CF5A5FE6ECDBQ37059979-36A809F9-A17C-4B5E-B6C8-36727A41FE35Q37104833-25B3D78D-1B5A-410A-864E-98015328401EQ37203610-5BD1F28E-4E66-4007-9686-CDEA3404FBA4Q37290852-72EEDAE3-5CC5-4798-915A-972A8A7B0E3BQ37290923-EBB1A1EC-42FF-4B33-8861-BA4600605D0CQ37467757-B68B63DA-2153-45E8-BE2B-14E0DF618F24Q37715255-22053D8E-DA34-432A-BF9D-33403C1A5EE2Q37927084-E68EC32F-F4FB-4AA5-8296-66A12B718D32Q37992118-5A2ECDD1-499D-4560-8B48-63DDFA4A926AQ38130235-F43EAEFA-640D-45AC-BB35-010CB46F8C86Q38218911-36583D2C-6F0D-4956-9D5E-AE75752578C4Q38795531-DE04B467-08FE-48E2-BE29-600914BBF486Q38843328-45BF4467-EFD6-4A3B-B728-FB86A0AE6D98Q38888403-971CC88C-13DF-40FF-8531-FB478853E5AAQ38971992-A122E93E-BEFA-4D34-92AB-FBF664733E50Q40095263-554F08E0-D3B8-4321-8FB3-085C66FA619DQ41503545-7AC8BDBD-CFAB-4595-8F74-A8D3202B2C8DQ41903758-7CA1F702-0719-4466-B739-98EF3014091CQ45115361-AD5ECC90-22AE-4C46-8681-CA84B8574B83Q45897216-6E639330-C858-4912-94F0-09AEF4A5340FQ47121440-71318563-D834-4970-9F4A-06A613B28B4DQ48325742-A321706C-8077-48A3-B598-A05B652EB757Q55024896-D1B26BB5-B01C-432B-B9E8-9E1057E1EC92Q55717336-1413B6B6-C55C-4FC1-81D7-E118AF35EA68
P2860
Risk factors for development or deterioration of Graves' ophthalmopathy
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Risk factors for development or deterioration of Graves' ophthalmopathy
@ast
Risk factors for development or deterioration of Graves' ophthalmopathy
@en
type
label
Risk factors for development or deterioration of Graves' ophthalmopathy
@ast
Risk factors for development or deterioration of Graves' ophthalmopathy
@en
prefLabel
Risk factors for development or deterioration of Graves' ophthalmopathy
@ast
Risk factors for development or deterioration of Graves' ophthalmopathy
@en
P2860
P356
P1433
P1476
Risk factors for development or deterioration of Graves' ophthalmopathy
@en
P2093
Marius N Stan
Rebecca S Bahn
P2860
P304
P356
10.1089/THY.2010.1634
P577
2010-07-01T00:00:00Z